Clinical Trial Update: Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating Baxdrostat in combination with dapagliflozin for heart failure and cardiovascular death, and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Baxdrostat (Baxdrostat)
• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Heart Failure | Phase 3 | Status: RECRUITING